Suspensions are pharmaceutical dosage forms consisting of insoluble active ingredients dispersed in a base vehicle. An ideal suspension should be uniform in content so each dose contains an equivalent amount of one or more — most likely one — active pharmaceutical ingredients (APIs). We briefly review oral suspensions and why content uniformity is vital in compounded preparations, as well as showcase the most studied oral suspension, in the following article.

The fundamental purpose of hospice is to help patients retain comfort, dignity and quality of life as they approach the end of life. During this stage, nausea and vomiting — either caused by medication side effects or from symptoms of a disease — are common. These and other side effects may lead to unnecessary stress and patient discomfort. In the following article, we review a commonly used topical gel that lessens nausea and vomiting, as well as the PCCA base vehicle that may enhance penetration of active pharmaceutical ingredients (APIs).

The numbers are in — forecasters predict 1.1 billion women worldwide will experience menopause in 2025. In the U.S., more than 1 million women reach menopause each year, and more than 75 percent of these women are employed during menopause transition years. Research conducted by the National Institute on Aging indicates menopausal hormone therapy (MHT) reduced the severity of menopause symptoms while elevating mood, sexual function, cardiovascular and brain health.

USP 800 discusses Environmental Quality and Control (Section 6) related to environmental wipe sampling for hazardous drug (HD) surface residue. This is not a requirement in USP 800; instead, it is stated that this should be performed routinely. What does this mean for those who handle HDs and why should compounders consider performing routine HD wipe sampling?

One of the most valuable benefits of PCCA membership is access to our knowledgeable Research & Development department and their compounding base innovations. Their creativity has led the industry and provided resources that benefit thousands of patients every day. This post focuses on a powerful base launched in 2023, EctoSeal P2G, and its application in one of the most common dermatological conditions — nail fungus (onychomycosis).

Sections of the FDA’s Drug Quality and Security Act (DQSA) distinguish compounding pharmacies (503A) from outsourcing facilities (503B). Due to several factors, many of which are related to drug shortages and the USP 797/USP 800 updates, 503A pharmacies are considering partnering with 503B entities for compounded sterile preparations and/or hazardous materials. We’ll discuss the differences between 503A pharmacies and 503B outsourcing facilities, review Section 503B and summarize how to effectively evaluate 503B compounding pharmacies for a potential partnership.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized metabolic health and weight management, leading to a host of new weight loss wonder drugs. But did you know that recent evidence shows these new drugs may do more than just help with weight loss and diabetes? And at a fraction of the standard dose?

Our Profiles in Personalized Medicine highlights Peoples Compounding Center in Austin, Texas. Nicola Trevis, BS, RPhT, Pharmacy Director, shares what “Compounding: It’s Personal” means to the team, their enduring relationship with PCCA and much more. Peoples Compounding Center has been a proud PCCA member since 1985.

Individuals who suffer from symptoms of gastrointestinal, autoimmune, dermatological and pain conditions make up 80% of the patient population. But here’s the good news: multiple studies indicate that low-dose naltrexone (LDN) may potentially help many of these conditions. Take a sneak peek at topics our Clinical Services team will discuss during the Low-Dose Naltrexone One-Day Virtual Conference on Thursday, November 21, 2024.

Perimenopause is a unique phase in a woman’s life, marked by fluctuating hormones and a wide range of symptoms. Hormone replacement therapy (HRT) can offer relief, but a one-size-fits-all approach may not yield the best results. A personalized approach, tailored to each woman’s unique hormonal profile, lifestyle and symptoms, can make all the difference in managing this transition effectively. Let’s explore the factors that contribute to low estrogen, the role of cortisol and progesterone, and why a customized approach to HRT is essential for perimenopausal women.